Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
Add more filters










Publication year range
1.
Anticancer Res ; 32(7): 2855-62, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22753748

ABSTRACT

In this study, we investigated the antiproliferative and anti-invasive mechanism action of sodium valproate (VPA), an inhibitor of histone deacetylase (HDAC) activity, in combination with the rexinoid 6-OH-11-O-hydroxyphenanthrene (IIF), a ligand of retinoid X receptor (RXR), in the HT-29 and LoVo colon cancer cell lines. VPA inhibited HDAC-1 and increased RXRγ expression. VPA and IIF reduced viability in a dose- and time-dependent manner. The combined use of VPA and IIF enhanced the apoptosis induction. In particular, the BCL2 level decreased, while levels of BAX, cleaved caspase-3 and caspase-9 increased. The same treatment also reduced invasiveness of HT-29 cell line through the inhibition of metalloproteinase-9 (MMP9) expression, and MMP9 and MMP2 activity, with an increase of tissue inhibitors of MMPs TIMP1 and TIMP2. In conclusion, VPA and IIF have strong proapoptotic and anti-invasive effects in the HT-29 colon cancer cell line and their effects are enhanced when used together.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Colonic Neoplasms/drug therapy , Apoptosis/drug effects , Caspase 3/metabolism , Caspase 9/metabolism , Colonic Neoplasms/pathology , Dose-Response Relationship, Drug , HT29 Cells , Histone Deacetylase Inhibitors/administration & dosage , Humans , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Neoplasm Invasiveness , Retinoid X Receptor gamma/metabolism , Tretinoin/administration & dosage , Tretinoin/analogs & derivatives , Valproic Acid/administration & dosage , bcl-2-Associated X Protein/metabolism
2.
Oncol Rep ; 21(4): 1083-9, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19288012

ABSTRACT

Experimental data from in vitro and in vivo models indicate that peroxisome proliferator-activated receptor (PPAR) ligand activation regulates differentiation and induces cell growth arrest and apoptosis in a variety of cancer types. Thiazolidinediones such as ciglitazone (CGZ) constitute the most well-known synthetic ligands for PPARgamma. We previously reported a remarkable antitumor effect of the retinoid 6-OH-11-O-hydroxyphenantrene (IIF), synthetic retinoid X receptors (RXRs) agonist, on many cancer cell lines. Since PPARs bind to DNA as heterodimers with RXRs, in this study we investigated if IIF potentiates the antitumoral properties of the PPARgamma ligand CGZ in glioblastoma U87MG and melanoma G361 cells. Our results show that either IIF or CGZ inhibited cell growth and tissue invasion ability, but these properties were enhanced by using IIF and CGZ in combined treatment. Since matrix metalloproteinases (MMPs) play a major role in tumor cell invasion, we analyzed the effect of IIF and CGZ on MMP2 and MMP9 activity and expression. The addition of IIF to CGZ resulted in a decrease of MMP2 and MMP9 expression and activity, higher than when each agent was used alone. Furthermore, treatment with IIF and/or CGZ enhanced PPARgamma expression but both agents in combined treatment caused the maximum efficiency. Finally, we demonstrated that IIF can potentiate PPARgamma trascriptional activity induced by CGZ, by evaluation of peroxisome proliferator-responsive element transactivation. In conclusion, these findings suggest that the RXR selective retinoid IIF, in combination with the PPARgamma ligand CGZ, may provide a therapeutic advantage in cancer treatment.


Subject(s)
Antineoplastic Agents/administration & dosage , Neoplasms/drug therapy , PPAR gamma/agonists , Retinoid X Receptors/agonists , Thiazolidinediones/administration & dosage , Tretinoin/analogs & derivatives , Cell Line, Tumor , Cell Movement/drug effects , Drug Synergism , Humans , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Neoplasm Invasiveness , Neoplasms/pathology , PPAR gamma/physiology , Retinoid X Receptors/physiology , Tretinoin/administration & dosage
3.
Anticancer Res ; 28(1A): 283-8, 2008.
Article in English | MEDLINE | ID: mdl-18383858

ABSTRACT

All-trans retinoic acid (RA) induces complete remission in a high proportion of patients with acute promyelocytic leukemia (APL). Nevertheless, most of these patients develop RA resistance and relapse. In an attemp to mimic clinical conditions for the treatment of leukemia, a stably RA-resistant subclone of the human promyelocytic leukemia cell line HL60 (HL60-R) was developed to study the antiproliferative and proapoptotic effect of the retinoid IIF (6-OH-11-O-hydroxyphenantrene) in comparison with RA. Moreover whether the inhibitor of histone deacetylase (HDAC) activity, valproic acid (VPA), could enhance sensitivity to retinoids in HL60-R cells was evaluated. Finally, the effect of IIF on the expression of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp) was evaluated. It was found that IIF strongly suppressed cell proliferation (as measured by growth curves) and induced apoptosis (as measured by DNA fragmentation and Annexin V detection assays), while RA was practically ineffective. The addition of VPA to IIF accentuated the antiproliferative effect of IIF alone and increased apoptosis; the combination of VPA with RA allowed growth arrest. Moreover IIF caused a reduction of transmembrane transporter expression, particularly of P-gp, as shown by Western blotting. Our results suggest that IIF may be useful in controlling the proliferation of RA-resistant leukemia cells, especially in combination with an HDAC inhibitor, such as VPA.


Subject(s)
Leukemia, Promyelocytic, Acute/drug therapy , Tretinoin/analogs & derivatives , Tretinoin/pharmacology , Valproic Acid/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis , Apoptosis/drug effects , Cell Growth Processes/drug effects , Drug Resistance, Neoplasm , HL-60 Cells , Humans , Leukemia, Promyelocytic, Acute/metabolism , Leukemia, Promyelocytic, Acute/pathology , Multidrug Resistance-Associated Proteins/biosynthesis
4.
Oncol Rep ; 18(4): 1015-21, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17786368

ABSTRACT

Glioblastomas, the most malignant and prevalent brain tumors which remain incurable, are characterized by both extensive proliferation and invasive growth. We previously reported a remarkable antitumoral effect of the retinoid 6-OH-11-O-hydroxyphenantrene (IIF) on neuroblastoma, leukemia and colon carcinoma cells. In this study we examined the effect of IIF on proliferation, apoptosis and cell invasion in the human glioblastoma cell line U87MG, in comparison with all-trans-retinoic acid (RA). Our results showed that both retinoids induced cell growth inhibition and apoptosis in a dose- and time-dependent manner. We also demonstrated that the invasive ability of glioblastoma cells decreased after treatment with IIF or RA. Since cell invasion involves a complex system of tightly regulated proteases, matrix metalloproteinases (MMPs) and their specific inhibitors, tissue inhibitors of MMPs (TIMPs), we analysed the effect of IIF on MMP and TIMP expression in comparison with RA. Treatment with both retinoids resulted in a marked decrease of MMP2 and MMP9 expression and of lytic activity of MMP2. In addition, exposure to IIF led to enhanced expression of TIMP2. Collectively, our results demonstrated the effectiveness of both IIF and RA in inhibiting proliferation, cell migration, and the invasive potential of glioblastoma U87MG cells. Notably, the anticancer activity of IIF, on the whole, was more pronounced than that of RA. Therefore, these findings, besides providing further evidence that IIF may be a powerful tool in the development of cancer treatments, suggest that IIF may have therapeutic potential against the invasiveness of brain tumors.


Subject(s)
Antineoplastic Agents/pharmacology , Brain Neoplasms/drug therapy , Cell Movement/drug effects , Cell Proliferation/drug effects , Glioblastoma/drug therapy , Tretinoin/analogs & derivatives , Tretinoin/pharmacology , Annexin A5/metabolism , Blotting, Western , Brain Neoplasms/pathology , Glioblastoma/pathology , Humans , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Neoplasm Invasiveness/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Neoplasm/genetics , RNA, Neoplasm/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-2/genetics , Tissue Inhibitor of Metalloproteinase-2/metabolism , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/pathology
5.
In Vivo ; 20(6A): 729-33, 2006.
Article in English | MEDLINE | ID: mdl-17203756

ABSTRACT

The development of multidrug resistance (MDR) is one of the major causes of failure in cancer therapy. The use of cell lines with acquired resistance to anticancer agents represents a very good tool for investigation into the possibility of reversal of MDR. In this study the ability of all-trans-retinoic acid (RA) and its derivative 6-OH-11-O-hydroxyphenanthrene (IIF; pat. WIPO W000 /117143) as antitumor agents was investigated in the human colon carcinoma cell line LoVo and in the counterpart resistant derivative LoVo/MDR cell line. Cell proliferation was measured by MTT assay, apoptosis was evaluated using DNA fragmentation and Annexin V detection assay. Retinoids suppressed cell proliferation in a time- and dose-dependent manner. Interestingly, IIF was significantly more effective than RA, particularly on LoVo/MDR cells. RA and IIF induced apoptosis in both cell lines, with IIF effect significantly higher than that of RA. Furthermore, on the basis that MDR phenotype is often caused by drug efflux due to overexpression of the membrane P-glycoprotein (P-gp), it was demonstrated that RA and IIF reduced P-gp synthesis in LoVo/MDR cells. Our results suggest that IIF could be a powerful tool in the development of colon carcinoma treatments, even when tumor cells present an MDR phenotype.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/pharmacology , Colonic Neoplasms/drug therapy , Drug Resistance, Multiple/drug effects , Drug Resistance, Neoplasm/drug effects , Tretinoin/analogs & derivatives , Tretinoin/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Apoptosis/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Dose-Response Relationship, Drug , Formazans/metabolism , Humans , Tetrazolium Salts/metabolism
6.
Anticancer Res ; 24(3a): 1779-83, 2004.
Article in English | MEDLINE | ID: mdl-15274355

ABSTRACT

Vitamin A and its metabolic forms, like all-trans retinoic acid (ATRA), are used with promising results in the treatment of many tumors. Two major problems in the clinical use of retinoids are that the doses needed for successful treatment are often toxic, leading to "hypervitaminosis A syndrome" and that patients often develop drug resistance. In order to find compounds that can overcome these problems, many new derivatives of retinoids have been synthesized and tested. Here we present a study on the effect of a new derivative of retinoic acid, IIF (pat. WIPO W0 00/17143), on growth and differentiation of two colon carcinomna cell lines, CaCo-2 and HT-29, with different degrees of tumorigenicity, the second one being more undifferentiated. The effect of IIF was compared with that of ATRA, whose antitumoral action on colon cancer cells and other tumoral cells is widely described in the literature. Besides exerting a strong antiproliferative effect, even higher than that of ATRA, IIF induced cellular differentiation, as demonstrated by the appearance of morphological (domes and microvilli formation) and biochemical (alkaline phosphatase induction) markers. Therefore, these findings indicate the new retinoid IIF as a possible candidate in the treatment of colon cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Colonic Neoplasms/drug therapy , Tretinoin/analogs & derivatives , Tretinoin/pharmacology , Caco-2 Cells , Cell Differentiation/drug effects , Cell Division/drug effects , Colonic Neoplasms/pathology , HT29 Cells , Humans
7.
Anticancer Res ; 23(2B): 1495-9, 2003.
Article in English | MEDLINE | ID: mdl-12820415

ABSTRACT

Neuroblastoma, a tumor originating from the sympathetic nervous system, is the most common extracranial malignant solid tumor of childhood. Human neuroblastoma cells may differentiate in vitro under treatment with a variety of biological agents and drugs. Among these, retinoic acid (RA) is quite potent and its effectiveness as a therapeutic agent is now being evaluated in clinical trials. As its pleiotropic biological activities may produce side-effects limiting clinical use, it is important to find new compounds that present the same effectiveness together with few side-effects. In this study we have explored the action of IIF, (pat. WIPO W0 00/17143) a new derivative of RA, as a differentiation inducer in the human neuroblastoma cell line TS12. In the same cell line, we have also compared the effect of IIF with that of all trans RA (ATRA) and of 9 cis RA (9cRA), with respect to morphological and biochemical differentiation and growth inhibition. Treatment with IIF resulted in a strong inhibition of proliferation and in a marked induction of neuronal differentiation as revealed by neurite extension, increase of actylcholinesterase (AchE) specific activity and tyrosine hydroxylase (TH) expression. The results demonstrate the effectiveness of this new retinoid as a differentiation inducer on neuroblastoma cells TS12. Furthermore, the differentiation-promoter and antimitotic activities of IIF were on the whole more pronounced than those of ATRA and 9cRA. Therefore our study suggests the evaluation of the new retinoid IIF as a therapeutic approach in the treatment of neuroblastoma.


Subject(s)
Antineoplastic Agents/pharmacology , Neuroblastoma/pathology , Tretinoin/pharmacology , Alitretinoin , Cell Differentiation/drug effects , Cell Division/drug effects , Drug Screening Assays, Antitumor , Humans , Neurites/drug effects , Phenotype , Tretinoin/analogs & derivatives , Tumor Cells, Cultured/cytology , Tumor Cells, Cultured/drug effects
8.
Mutat Res ; 465(1-2): 151-8, 2000 Feb 16.
Article in English | MEDLINE | ID: mdl-10708981

ABSTRACT

We previously found that beta-carotene (betaCT) can act as a co-carcinogenic agent enhancing the cell transforming activity of powerful carcinogens such as benzo(a)pyrene (B(a)P) and cigarette-smoke condensate (TAR) in an in vitro medium-term ( approximately 8 weeks) experimental model utilizing BALB/c 3T3 cells (Mutat. Res. 440 (1999) 83-90). Here, we investigated whether vitamin E (VitE) and alpha-naphthoflavone (alphaNF) are able to affect the co-carcinogenic activity of betaCT in terms of inhibiting B(a)P and TAR cell transforming potential. The following experimental schedules were performed: (i) cultures treated for 72 h with chemicals in various experimental combinations (acute treatment); (ii) cultures grown in presence of tester agents for the whole period of the assay (chronic treatment) to more closely mimic human exposure. While the co-carcinogenic potential of betaCT was confirmed on both B(a)P and TAR, the latter being ineffective by itself, we found in repeated experiments that the presence of VitE or alphaNF significantly reduced the betaCT's enhancing effect in the formation of transformation foci by B(a)P and TAR. The mechanism of the inhibition could be explained by the known ability of alphaNF to inhibit cytochrome P450-linked B(a)P-bioactivating monooxygenases, while VitE may contrast the prooxidant activity of betaCT (e.g., oxygen radicals overgeneration). While highlighting the importance of increasing knowledge of the role of single provitamins, vitamins and micronutrients, our findings also underline the potential advantages of combining several dietary supplements in in vitro preventive investigations.


Subject(s)
Benzo(a)pyrene/toxicity , Benzoflavones/pharmacology , Smoke/adverse effects , Vitamin E/pharmacology , beta Carotene/antagonists & inhibitors , beta Carotene/toxicity , 3T3 Cells , Animals , Benzo(a)pyrene/pharmacokinetics , Benzoflavones/administration & dosage , Biotransformation , Carcinogens/pharmacokinetics , Carcinogens/toxicity , Cell Transformation, Neoplastic/drug effects , Cocarcinogenesis , Drug Interactions , Humans , Mice , Plants, Toxic , Nicotiana , Vitamin E/administration & dosage , beta Carotene/administration & dosage
9.
Anticancer Res ; 20(6B): 4361-6, 2000.
Article in English | MEDLINE | ID: mdl-11205272

ABSTRACT

The hemopoietin stem cell factor (SCF) and its receptor c-kit are expressed in some tumoral cells, including neuroblastoma (NB) cells. We have investigated the effect of retinoic acid (RA), one of the most active differentiating agents on human NB cells, on the SCF production by human neuroblastoma cell lines. SCF concentration was determined by immunoenzymatic assay in the supernatants of seven neuroblastoma cell lines. All cell lines except one showed detectable amounts of SCF in the supernatant in basal culture conditions. A progressive increase pattern of the SCF concentration over time, was common to all SCF secreting cell lines, both unstimulated and RA-stimulated. Moreover, after 48 and 72 hours-exposure to RA, SCF concentrations were higher than in the untreated controls (p < 0.01). Membrane SCF mRNA isoform was also detected by reverse-transcription polymerase chain reaction. These effects demonstrated that RA, besides inducing neuronal differentiation, enhanced SCF production in neuroblastoma cell lines.


Subject(s)
Antineoplastic Agents/pharmacology , Keratolytic Agents/pharmacology , Neoplasm Proteins/metabolism , Neuroblastoma/metabolism , Proto-Oncogene Proteins c-kit/metabolism , Stem Cell Factor/metabolism , Tretinoin/pharmacology , Enzyme-Linked Immunosorbent Assay , Humans , Time Factors , Tumor Cells, Cultured/drug effects
10.
Anticancer Res ; 18(2A): 1099-103, 1998.
Article in English | MEDLINE | ID: mdl-9615772

ABSTRACT

Butyric acid has been shown in vitro to produce cytodifferentiation of a wide variety of neoplastic cells. The potential clinical use of this compound as a therapeutic agent is limited by its rapid metabolism. This has led to the examination, as potential antineoplastic agents, of compounds structurally correlated to butyrate, with longer biological half lives. In this study we investigated the effect in vitro of two butyrate analogues, tributyrin and butyramide, on inducing growth inhibition and expression of morphological and immunophenotypic properties, in human neuroblastoma cell lines. Treatment with tributyrin resulted in a strong inhibition of cell proliferation and in induction of extensive differentiation; on the contrary butyramide was scarcely effective or quite ineffective. These results demonstrate that tributyrin retains the effectiveness of butyrate and suggest that this analogue could have utility for cytodifferentiation therapy.


Subject(s)
Amides/pharmacology , Neuroblastoma/pathology , Trialkyltin Compounds/pharmacology , Cell Differentiation/drug effects , Cell Division/drug effects , Humans , Phenotype , Tumor Cells, Cultured
11.
Mutat Res ; 394(1-3): 29-35, 1997 Nov 27.
Article in English | MEDLINE | ID: mdl-9434840

ABSTRACT

Cytotoxic and cell-transforming activities of methyl thiophanate a systemic fungicide capable of entering plant cells and thus controlling fungal diseases that have already started were studied in an in vitro medium-term (6-8 weeks) experimental model utilizing BALB/c 3T3 cells. Cells were exposed to the chemical, dissolved in dimethyl sulfoxide, in the absence or presence of an exogenous metabolizing system derived from rat livers supplemented with cofactors (S9 mix). In the absence of metabolic activation, methyl thiophanate exerted cytotoxic activity, evidenced through the formation of cell colonies, at low doses (> 10 micrograms/ml). However, the cytotoxic activity was greatly reduced by the S9 mix-induced metabolic activation of the chemical. Without bioactivation, cell-transforming potential, evidenced through the induction of transformation foci, was observable only at the highest (weakly toxic) dose employed (25 micrograms/ml). On the contrary, in the presence of metabolic activation, the cell-transforming activity was detectable at all tested doses (i.e. from 20 to 200 micrograms/ml) and it was particularly evident in a level-II transformation amplification test when the cells were allowed to perform active proliferative activity. These results, providing further information on the activity of methyl thiophanate in multistep carcinogenesis as possible genotoxic and/or co-carcinogenic agent, may contribute to better evaluate the oncogenic risk to man.


Subject(s)
Carcinogens/pharmacology , Fungicides, Industrial/pharmacology , 3T3 Cells , Animals , Biotransformation , Cell Line, Transformed/drug effects , Cell Survival/drug effects , Mice , Mice, Inbred BALB C , Rats
12.
Anticancer Res ; 15(4): 1381-5, 1995.
Article in English | MEDLINE | ID: mdl-7654025

ABSTRACT

We investigated the effect on differentiation of genistein, an inhibitor of tyrosine protein kinase, and 1-(-5 isoquinolinylsulfonyl)-2-methylpiperazine (H7), an inhibitor of protein kinase C, in neuroblastoma cell lines. Growth inhibition and expression of morphological and biochemical properties were examined in the human neuroblastoma cell lines TS12 and SJNKP. Genistein and H7 induced neurite outgrowth, increased acetylcholinesterase activity and cell growth inhibition in both cell lines. These results underline that tyrosine protein kinase and protein kinase C may play a key role in the control of differentiation and proliferation of neural cells.


Subject(s)
Isoflavones/pharmacology , Neuroblastoma/pathology , Protein-Tyrosine Kinases/antagonists & inhibitors , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine , Cell Differentiation/drug effects , Cell Division/drug effects , Genistein , Humans , Immunophenotyping , Isoquinolines/pharmacology , Phosphorylation , Piperazines/pharmacology , Tumor Cells, Cultured
13.
Anticancer Res ; 13(2): 419-22, 1993.
Article in English | MEDLINE | ID: mdl-8517657

ABSTRACT

We have studied the effect of gamma radiation on differentiation in neuroblastoma cell lines AF8 and SJ-N-KP. Growth inhibition and morphological and biochemical differentiation have been examined following radiation exposure to 1-10 Gy. Gamma radiation induced marked growth inhibition and morphological differentiation in a dose-and time-dependent manner in both cell lines, and induced biochemical differentiation in AF8 cells.


Subject(s)
Gamma Rays , Neuroblastoma/radiotherapy , Acetylcholinesterase/metabolism , Cell Differentiation/radiation effects , Humans , Immunophenotyping , Neuroblastoma/enzymology , Neuroblastoma/pathology , Tumor Cells, Cultured/radiation effects
15.
Anticancer Res ; 12(3): 917-20, 1992.
Article in English | MEDLINE | ID: mdl-1622149

ABSTRACT

The effect of sodium butyrate (NaB) on cell growth and expression of morphological and biochemical properties was examined in the human neuroblastoma cell lines AF8 and SJ-N-KP. The obtained data show that NaB induced a marked growth inhibition and morphological differentiation, while it was ineffective in inducing biochemical differentiation.


Subject(s)
Butyrates/pharmacology , Cell Differentiation/drug effects , Cell Division/drug effects , Acetylcholinesterase/metabolism , Antibodies, Monoclonal , Butyric Acid , Cell Line , Chromogranin A , Chromogranins/analysis , HLA Antigens/analysis , HLA-DR Antigens/analysis , Humans , Immunohistochemistry , Neuroblastoma , Neurofilament Proteins/analysis , Phosphopyruvate Hydratase/analysis , Synaptophysin/analysis , Tumor Cells, Cultured
16.
Anticancer Res ; 11(5): 1885-9, 1991.
Article in English | MEDLINE | ID: mdl-1768060

ABSTRACT

The antineoplastic drug 4'-iodo-4'-deoxydoxorubicin (IDX), a new halogenated anthracycline (1), was examined as a differentiation inducing agent on the human neuroblastoma cell lines TS12 and SK-N-MC. IDX induced morphological and biochemical differentiation and growth inhibition. The effect of a combined treatment of IDX with retinoic acid (RA) and with nerve growth factor (NGF) respectively was then investigated. The responses of neuroblastoma cells to IDX alone and to these combined treatments were compared, with respect to neuritic outgrowth, acetylcholinesterase activity and cellular growth. The data obtained indicate that the combination of differentiation-inducing drugs may be able to enhance the effects of the same drugs given alone.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Neuroblastoma/pathology , Neurons/pathology , Acetylcholinesterase/metabolism , Cell Differentiation/drug effects , Doxorubicin/analogs & derivatives , Doxorubicin/pharmacology , Drug Screening Assays, Antitumor , Drug Synergism , Humans , Nerve Growth Factors/pharmacology , Neuroblastoma/enzymology , Neurons/enzymology , Tretinoin/pharmacology , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/enzymology , Tumor Cells, Cultured/pathology
17.
Anticancer Res ; 7(2): 247-50, 1987.
Article in English | MEDLINE | ID: mdl-3473974

ABSTRACT

On the basis that inhibition of cell proliferation may play a role in the differentiation process, we have studied the effect of the antineoplastic drug epirubicin, an antibiotic of the anthracycline group, on human neuroblastoma cell lines SK-N-MC, SK-N-SH, SJ-N-KP, TS12 and AF8. Epirubicin induced morphological and biochemical differentiation in these cultured cell lines; treatment with it stimulated the outgrowth of neurites and increased acetylcholinesterase activity.


Subject(s)
Doxorubicin/pharmacology , Neuroblastoma/pathology , Acetylcholinesterase/metabolism , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Line , Epirubicin , Growth Inhibitors/pharmacology , Humans , In Vitro Techniques , Time Factors
18.
Nutr Cancer ; 8(4): 267-72, 1986.
Article in English | MEDLINE | ID: mdl-3095797

ABSTRACT

The effect of vitamin A palmitate (VAP), vitamin A acetate (VAA), 2,3-tert-butyl-4-hydroxyanisole, and 2,6-di-tert-butyl-p-cresol (BHT) on mutagenesis induced by 7,12-dime-thylbenz[a]anthracene (DMBA) was examined in a human epithelial-like cell line. Cultures were exposed to DMBA with or without the antioxidant compound, and mutation frequencies were determined by selection against diphtheria toxin. A clear inhibition of mutagenesis was observed particularly with VAA and BHT.


Subject(s)
9,10-Dimethyl-1,2-benzanthracene , Antioxidants/pharmacology , Mutation/drug effects , Cell Line , Diterpenes , Humans , Retinyl Esters , Vitamin A/analogs & derivatives , Vitamin A/pharmacology
19.
Tumori ; 69(3): 191-4, 1983 Jun 30.
Article in English | MEDLINE | ID: mdl-6868135

ABSTRACT

Epichlorohydrin (ECHH) highly inhibited the tritiated thymidine uptake by human lymphocytes cultured in vitro, although the corresponding cell viability was unaffected. Furthermore, it elicited unscheduled DNA synthesis, acting as a DNA-damaging agent after its metabolic activation. ECHH also showed a clear toxic and mutagenic activity toward a human epithelial-like cell line, causing a decrease in cell viability and an increase in mutants resistant to 0.05 Lf/ml of diphtheria toxin.


Subject(s)
Chlorohydrins/toxicity , DNA/metabolism , Epichlorohydrin/toxicity , Mutagens/toxicity , Cell Line , Cell Survival/drug effects , Cells, Cultured , DNA Replication/drug effects , Diphtheria Toxin/antagonists & inhibitors , Drug Resistance , Epithelial Cells , Epithelium/drug effects , Humans , Lymphocytes/drug effects , Mutation , Thymidine/metabolism
20.
J Cancer Res Clin Oncol ; 105(1): 111-2, 1983.
Article in English | MEDLINE | ID: mdl-6339513

ABSTRACT

The mutagenic power of 1,2-dichloroethane, 1,2-dibromoethane, 1,2-diiodoethane was tested in the human cell line, EUE. In our mutagenic system, based on selection against diphtheria toxin, the halogenated compounds, 1,2-dichloroethane and 1,2-dibromoethane revealed a strong mutagenic effect, whereas 1,2-diiodoethane was not mutagenic at a concentration allowing survival of 41%.


Subject(s)
Ethylene Dibromide/pharmacology , Ethylene Dichlorides/pharmacology , Hydrocarbons, Brominated/pharmacology , Hydrocarbons, Chlorinated/pharmacology , Mutation/drug effects , Cell Line , Diphtheria Toxin , Dose-Response Relationship, Drug , Humans , Salmonella typhimurium/drug effects , Salmonella typhimurium/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...